公开(公告)号：US10144706B2

公开(公告)日：2018-12-04

申请号：US15689115

申请日：2017-08-29

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Kap-Sun Yeung ,  Katharine A. Grant-Young ,  Juliang Zhu ,  Mark G. Saulnier ,  David B. Frennesson ,  David R. Langley ,  Piyasena Hewawasam ,  Tao Wang ,  Zhongxing Zhang ,  Zhaoxing Meng ,  Li-Qiang Sun ,  Eric Mull ,  Paul Michael Scola

IPC: C07D207/12 ,  C07D217/18 ,  C07D237/06 ,  C07D205/04 ,  C07D207/14 ,  C07D207/16 ,  C07D211/22 ,  C07D211/66 ,  C07D211/90 ,  C07D213/38 ,  C07D213/73 ,  C07D213/79 ,  C07D213/85 ,  C07D231/12 ,  C07D239/26 ,  C07D277/28 ,  C07D295/088 ,  C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  C07D405/12 ,  C07D405/14 ,  C07D413/14 ,  C07D401/04 ,  C07D405/06 ,  C07D417/12 ,  C07D211/46 ,  C07D211/58 ,  C07D211/60 ,  C07D213/42 ,  C07D213/55 ,  C07C237/04 ,  C07C235/08 ,  C07C229/14 ,  C07C217/58 ,  C07C217/28 ,  C07C217/18 ,  C07C237/06 ,  C07C255/24 ,  C07C255/25

Abstract: The present disclosure generally relates to compounds useful as immunomodulators. Provided herein are compounds, compositions comprising such compounds, and methods of their use. The disclosure further pertains to pharmaceutical compositions comprising at least one compound according to the disclosure that are useful for the treatment of various diseases, including cancer and infectious diseases.

公开(公告)号：US09868743B2

公开(公告)日：2018-01-16

申请号：US14765906

申请日：2014-02-04

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Tao Wang ,  Zhongxing Zhang ,  Eric Gillis ,  Paul Michael Scola

IPC: A01N37/18 ,  A61K38/00 ,  A61P1/16 ,  C07D487/08 ,  C07D498/08 ,  A61K31/53

CPC classification number: C07D487/08 ,  A61K31/53 ,  C07D498/08

Abstract: Compounds of Formula I, including pharmaceutically acceptable salts thereof, are set forth, in addition to compositions and methods of using these compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV.

公开(公告)号：US20170101416A1

公开(公告)日：2017-04-13

申请号：US15312022

申请日：2015-05-19

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Tao WANG ,  Zhongxing Zhang ,  John F. Kadow

IPC: C07D491/048 ,  C07D405/10

CPC classification number: C07D491/048 ,  C07D307/84 ,  C07D405/10

Abstract: Compounds of Formula I, including their salts, as well as compositions and methods of using the compounds are set forth. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV: formula (I).

公开(公告)号：US20150329543A1

公开(公告)日：2015-11-19

申请号：US14725318

申请日：2015-05-29

Applicant: Bristol-Myers Squibb Company

Inventor： Tao Wang ,  Zhongxing Zhang ,  Nicholas A. Meanwell ,  John F. Kadow ,  Zhiwei Yin ,  Qiufen May Xue ,  Alicia Regueiro-Ren ,  John D. Matiskella ,  Yasutsugu Ueda

IPC: C07D471/04

CPC classification number: C07D471/04 ,  A61K31/496 ,  A61K45/06 ,  C07D491/048

Abstract: This invention provides compounds having drug and bio-affecting properties, their pharmaceutical compositions and method of use. In particular, the invention is concerned with azaindoleoxoacetyl piperazine derivatives. These compounds possess unique antiviral activity, whether used alone or in combination with other antivirals, antiinfectives, immunomodulators or HIV entry inhibitors. More particularly, the present invention relates to the treatment of HIV and AIDS.

Abstract translation: 本发明提供具有药物和生物影响性质的化合物，其药物组合物和使用方法。 特别地，本发明涉及氮杂吲哚乙酰基哌嗪衍生物。 这些化合物具有独特的抗病毒活性，无论是单独使用还是与其他抗病毒药，抗感染剂，免疫调节剂或HIV进入抑制剂组合使用。 更具体地说，本发明涉及艾滋病毒和艾滋病的治疗。

公开(公告)号：US20150322085A1

公开(公告)日：2015-11-12

申请号：US14762537

申请日：2014-01-23

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Tao Wang ,  Zhiwei Yin ,  Zhongxing Zhang ,  Paul Michael Scola

IPC: C07D498/08 ,  A61K31/53 ,  A61K45/06 ,  C07D251/52

CPC classification number: A61K31/53 ,  A61K38/13 ,  A61K38/20 ,  A61K38/21 ,  A61K45/06 ,  C07D251/52 ,  C07D498/08 ,  A61K2300/00

Abstract: Compounds of Formula I, including pharmaceutically acceptable salts thereof, are set forth, in addition to compositions and methods of using these compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV.

Abstract translation: 除了使用这些化合物的组合物和方法之外，还列举了式I化合物，包括其药学上可接受的盐。 该化合物具有抗丙型肝炎病毒（HCV）的活性，可用于治疗HCV感染者。

公开(公告)号：US20150210684A1

公开(公告)日：2015-07-30

申请号：US14419559

申请日：2013-08-07

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Tao Wang ,  Zhongxing Zhang ,  John F. Kadow ,  Nicholas A. Meanwell ,  Edward H. Ruediger ,  Clint A. James ,  Daniel H. Deon ,  David J. Carini ,  Barry L. Johnson

IPC: C07D471/04 ,  A61K45/06 ,  A61K31/4545 ,  C07D401/06 ,  A61K31/454

CPC classification number: C07D471/04 ,  A61K31/454 ,  A61K31/4545 ,  A61K45/06 ,  C07D401/06

Abstract: Compounds of Formula I, including pharmaceutically acceptable salts thereof: formule (I): wherein A is selected from the group consisting of: formule (II) and wherein Z is selected from the group consisting of: formule (III): and. are useful as HIV attachment inhibitors.

Abstract translation: 式I化合物，包括其药学上可接受的盐：式（I）：其中A选自：结构（II），并且其中Z选自：基团（III）：和。 可用作HIV附着抑制剂。

公开(公告)号：US20150025240A1

公开(公告)日：2015-01-22

申请号：US14249638

申请日：2014-04-10

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Yasutsugu Ueda ,  Timothy P. Connolly ,  John F. Kadow ,  Nicholas A. Meanwell ,  Tao Wang ,  Chung-Pin H. Chen ,  Kap-Sun Yeung ,  Zhongxing Zhang ,  David Kenneth Leahy ,  Shawn K. Pack ,  Nachimuthu Soundararajan ,  Pierre Sirard ,  Kathia Levesque ,  Dominique Thoraval

IPC: C07F9/06 ,  C07F9/6561

CPC classification number: A61K31/675 ,  A61K31/497 ,  A61K31/519 ,  A61K45/06 ,  C07C215/10 ,  C07D471/04 ,  C07F9/062 ,  C07F9/5728 ,  C07F9/65515 ,  C07F9/65586 ,  C07F9/6561

Abstract: This invention provides for prodrug Compounds I, pharmaceutical compositions thereof, and their use in treating HIV infection. wherein: X is C or N with the proviso that when X is N, R1 does not exist; W is C or N with the proviso that when W is N, R2 does not exist; V is C; E is hydrogen or a pharmaceutically acceptable salt thereof; and Y is selected from the group consisting of Also, this invention provides for intermediate Compounds II useful in making prodrug Compounds I. wherein: L and M are independently selected from the group consisting of C1-C6 alkyl, phenyl, benzyl, trialkylsilyl, -2,2,2-trichloroethoxy and 2-trimethylsilylethoxy.

公开(公告)号：US08916702B2

公开(公告)日：2014-12-23

申请号：US13758624

申请日：2013-02-04

Applicant: Bristol-Myers Squibb Company

Inventor： Tao Wang ,  Paul Michael Scola ,  Zhongxing Zhang ,  Zhiwei Yin ,  Qian Zhao

IPC: C07D251/52 ,  A61K31/53 ,  A61P31/14 ,  C07D401/14 ,  C07D513/04 ,  C07D405/12 ,  C07D403/12 ,  C07D413/12 ,  C07D417/12 ,  C07D401/12

CPC classification number: C07D513/04 ,  C07D251/52 ,  C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  C07D405/12 ,  C07D413/12 ,  C07D417/12

Abstract: The disclosure provides compounds of formula I, including pharmaceutically acceptable salts, as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV.

公开(公告)号：US10125111B2

公开(公告)日：2018-11-13

申请号：US15551002

申请日：2016-02-17

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Tao Wang ,  Zhiwei Yin ,  Zhongxing Zhang ,  John F. Kadow

IPC: C07D307/82 ,  C07D307/84 ,  C07D405/04 ,  C07D405/12

Abstract: Compounds of Formula I, including their salts, as well as compositions and methods of using the compounds are set forth. The compounds have activity against hepatitis C virus, (HCV) and may be useful in treating those infected with HCV.

公开(公告)号：US20180030016A1

公开(公告)日：2018-02-01

申请号：US15551002

申请日：2016-02-17

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Tao Wang ,  Zhiwei Yin ,  Zhongxing Zhang ,  John F. Kadow

IPC: C07D307/82 ,  C07D405/12 ,  C07D405/04

CPC classification number: C07D307/82 ,  C07D307/84 ,  C07D405/04 ,  C07D405/12

Abstract: Compounds of Formula I, including their salts, as well as compositions and methods of using the compounds are set forth. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV: